Septerna, Inc. (SEPN)
Nasdaq: SEPN · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2023
Who owns Septerna, Inc.
As filed with the SECHolders of 5% or more
3
Third Rock Ventures V, L.P. holds 14% of Common Stock, $0.001 par value per share, as its SCHEDULE 13G/A filed May 9, 2025 says.
Directors and officers
21
report now, of 22 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Third Rock Ventures V, L.P.
SCHEDULE 13G/A · filed May 9, 2025 · Common Stock, $0.001 par value per share · 14% in Feb 13, 2025
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share
Driehaus Capital Management LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 10.5% in Jun 10, 2025
Bvf Partners L P/il
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 9.9% in May 15, 2025
What SEPN reports owning in othersstakes of 5% or more, and other ties
Septerna, Inc. reports no stake in another company in the record.
Insider tradesForm 4
27sales
0purchases
24sales on a scheduled plan
4people selling
$68.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 19, 2025 to Oct 19, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 19, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Shah Rajeev M. | director | 2 | $63.5M | 0 | 0 | $0 |
| Third Rock Ventures Gp Vi, L.P. | 10% owner | 2 | $7.4M | 2 | 0 | $0 |
| Shaikhly Samira | Chief People Officer | 8 | $2.8M | 8 | 0 | $0 |
| Bhatt Elizabeth | President and COO | 9 | $1.6M | 9 | 0 | $0 |
| Long Daniel D. | SVP, Drug Discovery | 8 | $1.0M | 7 | 0 | $0 |